TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.
Dolutegravir is an anti-bacterial drug. 
( z1 drug :name ( z2 name :op "Dolutegravir" ) :ARG0-of ( z3 counter :ARG1 ( z4 bacterium ) ) )